TrumpRx reaches mainly weight-loss drugs at launch, experts say

TrumpRx.gov currently lists discounts largely for GLP-1 weight-loss medications and fewer than 45 drugs in total, with most offers coming from a single manufacturer and only five companies listed so far, Reuters reports.

President Donald Trump unveiled a new prescription drug website, TrumpRx.gov, which the administration presents as a central effort to lower U.S. drug prices. The site focuses heavily on negotiated discounts for GLP-1 weight-loss medications. While multiple manufacturers struck deals with the administration, only a small number had listed products on the site at launch. Officials said more drugs from additional companies would be added in the coming months. Key details: - TrumpRx lists discounts on fewer than 45 drugs in total. - More than 30 of the listed drugs come from a single manufacturer, Pfizer. - Sixteen major drugmakers struck "most-favored nation" deals with the administration, but only five companies had listed drugs on the site as of Friday. - The site provides coupons or links to manufacturer-run sites rather than selling drugs directly. - Reported discounts range from about 33% to over 90%, but some medicines still have high out-of-pocket costs (for example, Xeljanz is listed at roughly one-third off but still over $1,500 for a monthly dose). - The administration negotiated GLP-1 price cuts to as low as $149 a month and around $350 a month on average from prices that had exceeded $1,000 a month; the fertility drug Gonal-F is listed at $168, an 83% cut from the list price. Summary: The immediate reach of TrumpRx appears limited, with concentrated discounts on a small number of drugs and heavy representation from one manufacturer. Experts cited in the reporting say a minority of patients may find better deals through the site, while many will likely continue to rely on their insurance coverage for lower costs. Officials have said additional drugs will be added in coming months, and further changes to the site's listings were described as expected but the timeline for broader coverage is undetermined at this time.